Navigation Links
Help for Psoriasis

New research shows the drug efalizumab may reduce symptoms of psoriasis and improve patients’ quality of life.//

Researchers from Loyola University studied more than 550 patients who had psoriasis. Patients received weekly injections of efalizumab (Raptiva) or a placebo for three months. Researchers evaluated the extent of each patient’s condition and rated the degree of scaling and thickness. Patients also completed a questionnaire that measured their quality of life and severity of symptoms.

Results of the study show patients who received efalizumab experienced a significant improvement in their symptoms and quality of life. Patients were considered to have improved if they scored at least 75 percent on the Psoriasis Area and Severity Index. Twenty-seven percent of the patients treated with efalizumab scored at least 75 percent, while only 4 percent of patients in placebo group achieved this score. Patients who took efalizumab also reported a better quality of life than those in the placebo group.

Efalizumab is a biologic drug that blocks immune cells. Researchers say the drug modulates T-cells, which bolster the body’s immune response. Kenneth Gordon, M.D., from the Loyola Psoriasis Center, says, “Biologics are injected, instead of swallowed and block immune cells that produce the dry, flaky skin.”

Psoriasis is triggered by an immune system response that causes skin cells to grow too quickly. The skin cells do not mature normally, and the skin piles up, causing red, scaly lesions to form. About 5 million people in the United States are affected by psoriasis. There is currently no cure, but researchers say new treatments, including biologics, are helping to improve the condition for many patients.

'"/>




Page: 1

Related medicine news :

1. New and unique treatment for Psoriasis patients
2. Comparing Psoriasis Treatments
3. Psoriasis Increases Cancer Risk
4. Managing Patients With Psoriasis
5. Effective Treatment Option For Psoriasis
6. Smoking Aggravates Psoriasis
7. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
8. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
9. Psoriasis raises risk for heart attack
10. Psoriasis Associated With Increased Risk For Heart Attack
11. Remicade Therapy Effective in Treating Severe Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... MD (PRWEB) , ... March 29, 2017 , ... ... is proud to announce the finalization of the company’s executive management team with prominent ... and leading operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who ...
(Date:3/29/2017)... Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... of a growing number of cancers and is touted to be the next revolution ... treatment, thus far, has been in the form of immune checkpoint inhibitors such as ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wharton School of the University of Pennsylvania is ... made a $10 million gift to establish the Ken Moelis and Julie Taffet ... to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... to their offering. ... The ablation device global market is expected to grow at ... Ablation is the minimally invasive therapeutic tissue excision procedure ... tissue removal, to the removal of abnormally conducting cardiac tissue in ...
(Date:3/29/2017)...   Royal Philips (NYSE: PHG, AEX: ... PathAI, a company that develops artificial intelligence technology ... develop solutions that improve the precision and accuracy ... The partnership aims to build deep learning applications ... intelligence to be applied to massive pathology data ...
(Date:3/29/2017)... , March 29, 2017 On March 28, the U.S. ... adult patients with relapsing forms of multiple sclerosis (MS) ... first drug approved by the FDA for PPMS. Ocrevus ... professional.  "Multiple sclerosis can have a ... Dunn , M.D., director of the Division of Neurology ...
Breaking Medicine Technology: